
News|Articles|February 20, 2025
Social Media's Influence on Young Women's Reproductive Decisions
Author(s)Miranda Schmalfuhs
In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.
Advertisement
Advertisement
Mis- and disinformation on social media is a growing concern for both pharmaceutical companies and patients alike. Distrust in the various different platforms leave patients looking for guidance from any "trusted source," regulated or not, and the consequences could be disastrous. Young adults are increasing looking to their online parasocial relationships for advice on many topics, including health and medical care. This is just one of many challenges that the spread of misinformation presents.
Related to this article

Four principles for getting AI agents past the pilot phase in regulated pharma manufacturing.

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

As specialty drug complexity grows, agentic technology puts the right access, adherence, and affordability resources at the provider’s fingertips at prescribing.

J&J’s separations of Kenvue and DePuy Synthes test whether Innovative Medicine and MedTech create more value together than apart.

Parexel’s Stacy Hurt explains why AI can speed up clinical research but can’t replace the lived experience of patients.

The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.

White House withdraws Dr. Heidi Overton’s FDA commissioner nomination amid Senate GOP pushback, Pfizer and Verismo advance in vivo CAR-T manufacturing through new licensing deals, and Infinitus’s Ankit Jain discusses balancing workloads between humans and agentic AI.
Advertisement
Advertisement

